Back to AGIOView Full Landscape
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
9 competitors in Sickle Cell Disease
TRAXSickle cell gene-editing therapy (name not stated)
NVOetavopivat
VRTXCasgevy
Phase 3BEAMBEAM-101
Phase 2HSCSWr-ATG
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/9/2022
Pyrukynd
Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
